Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Humoral response and safety of the BNT162b2 and mRNA-1273 COVID-19 vaccines in allogeneic hematopoietic stem cell transplant recipients: An observational study

Masashi Nishikubo a, Yoshimitsu Shimomura a,b,* , Hayato Maruoka c, Seiko Nasu c, Tomomi Nishioka d, Kenji Sakizono e, Satoshi Mitsuyuki a, Tomoyo Kubo a, Naoki Okada a, Daishi Nakagawa a, Kimimori Kamijo a, Hiroharu Imoto a, Ryusuke Yamamoto f, Yuya Nagai a, Nobuhiro Hiramoto a, Satoshi Yoshioka a, Noboru Yonetani a, Akiko Matsushita a, Chisato Miyakoshi e, Asako Doi f, Takayuki Ishikawa a

a Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Hyogo, 650-0047, Japan
b Department of Environmental Medicine and Population Science, Graduate School of Medicine, Osaka University, Osaka, 565-0871, Japan
c Department of Clinical Laboratory, Kobe City Medical Center General Hospital, Kobe, Hyogo, 650-0047, Japan
d LSI Medience Laboratory, Kobe City Medical Center General Hospital, Kobe, Hyogo, 650-0047, Japan
e Department of Research Support, Center for Clinical Research and Innovation, Kobe City Medical Center General Hospital, Kobe, Hyogo, 650-0047, Japan
f Department of Infectious Diseases, Kobe City Medical Center General Hospital, Kobe, Hyogo, 650-0047, Japan

ARTICLE INFO

Keywords:
Allogeneic COVID-19 SARS-CoV-2 Transplantation Vaccine

ABSTRACT

Background: The effectiveness of mRNA COVID-19 vaccines and the optimal timing of vaccine administration in allogeneic hematopoietic stem cell transplantation (Allo-HSCT) recipients remains inadequately investigated. We examine the effectiveness and safety of mRNA COVID-19 vaccines in allo-HSCT recipients.

Method: This prospective observational study included 44 allo-HSCT recipients and 38 healthy volunteers. The proportion of subjects acquiring anti-S1 IgG antibodies were considered as the primary endpoint. The occurrence of adverse events after vaccination and objective deterioration of chronic graft-versus-host disease (GVHD) were defined as secondary endpoints. In addition, we compared the geometric mean titers (GMT) of anti-S1 antibody titers in subgroups based on time interval between transplantation and vaccination.

Results: A humoral response to the vaccine was evident in 40 (91%) patients and all 38 healthy controls. The GMT of anti-S1 titers in patients and healthy controls were 277 (95% confidence interval [CI]: 120–643) BAU/mL and 532 (95% CI 400–708) BAU/mL, respectively. (p = 0.603). A short time interval between transplantation and vaccination (≤6 months) was associated with low anti-S1 IgG antibody titers. No serious adverse events and deterioration of chronic GVHD were observed. Only one case of new development of mild chronic GVHD was recorded.

Conclusion: Messenger RNA COVID-19 vaccines induce humoral responses in allo-HSCT recipients and can be administered safely.

1. Introduction

Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) recipients are at a risk of severe coronavirus disease 2019 (COVID-19), with a 30-day survival rate of 68% if previously unvaccinated [1]. They respond to most conventional vaccines, albeit to a lower extent than healthy individuals during the first few months or years after transplantation. Some conventional vaccines can induce a serological response in allo-HSCT recipients as early as 3–6 months post transplantation. As to COVID-19 vaccines, some societies, such as the American Society of Transplantation and Cellular Therapy and American Society of Hematology, recommend mRNA COVID-19 vaccination

* Corresponding author. Department of Hematology, Kobe City Medical Center General Hospital, 2-1-1 Minami-machi, Minatojima, Chuo-ku, Kobe, Hyogo, 650-0047, Japan.
E-mail address: shimomura_0119@yahoo.co.jp (Y. Shimomura).

https://doi.org/10.1016/j.jiac.2022.11.010
Received 5 September 2022; Received in revised form 18 November 2022; Accepted 21 November 2022
Available online 26 November 2022
1341-321X/© 2022 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
as early as three months after allo-HSCT based on the high level of protection afforded to the vaccinated participants and overall safety of the vaccine in clinical trials [2].

The effectiveness of conventional vaccines in allo-HSCT recipients is influenced by complex humoral and cell-mediated immunodeficiencies that evolve over time, transplant procedures, and prevention and treatment of graft-versus-host disease (GVHD) [3]. However, factors associated with humoral response to mRNA COVID-19 vaccines are not well established, and the optimal timing of vaccine administration remains unknown. Moreover, data regarding the safety of mRNA COVID-19 vaccines, including the worsening or newly-development of chronic GVHD, are warranted. Therefore, in the present study, we examined the effectiveness and safety of COVID-19 mRNA vaccines in allo-HSCT recipients and factors associated with an impaired humoral response.

2. Methods

2.1. Study design and participants

This prospective study investigated the efficacy and safety of BNT162b2 and mRNA-1273 COVID-19 vaccines in allo-HSCT recipients admitted to Kobe City Medical Center General Hospital. Patients were recruited between June 2021 and September 2021. Allo-HSCT recipients over the age of 16 years with >3 months elapsed since transplantation were included in the study. Exclusion criteria were as follows: 1) patients with a known history of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and 2) those with comorbidities of autoimmune diseases, including systemic lupus erythematosus, Sjögren’s syndrome, inflammatory myositis, mixed connective tissue disease, systemic sclerosis, rheumatoid arthritis, polymyalgia rheumatica, psoriatic arthritis, spondylarthropathies, vasculitis syndromes, inflammatory bowel diseases, Guillain–Barré syndrome, multiple sclerosis, and neuromyelitis optica. The control group, comprising healthy volunteers aged >20 years without a history of COVID-19, in our previous study, in which we investigated vaccine efficacy in patients exposed to anti-CD20 antibodies, also served as the control group in the present study [4]. The study was approved by the Institutional Review Board of Kobe City Medical Center General Hospital (approval no.: zn210708). Informed consent was obtained from all participants.

2.2. Procedures

The blood serum samples of study participants were collected 14–90 days after they received the second dose of vaccine. Data on demographics, complete blood count, diagnosis, disease status, and treatment history were extracted from medical records. Details of the treatment history included conditioning regimens, donor type, GVHD prophylaxis, and immunosuppressant intake. For second allo-HSCT recipients, the details of their second allo-HSCT were employed, and their transplant day was set as the day of their second transplantation. In addition, all subjects were enquired about any local or systemic adverse events within 7 days after each vaccine dose through a questionnaire. Adverse events were defined as local pain, redness or edema, axillary lymphadenopathy, fatigue, myalgia, fever, chills, headache, nausea or vomiting, anaphylaxis, and subjective worsening of any chronic GVHD symptoms. To assess the objective deterioration of chronic GVHD signs and symptoms, attending physicians reported National Institutes of Health (NIH) scores for chronic GVHD grading both at the day of inclusion and of blood sampling (genital tract examination was skipped) [3]. The objective deterioration of chronic GVHD was defined as an increase in the sum of the NIH score.

2.3. Anti-SARS-CoV-2 antibody titer evaluation

Abbott Architect SARS-CoV-2 IgG Quant II chemiluminescent microparticle immunoassay (Abbott, Sligo, Ireland) was used to detect IgG antibodies to the receptor-binding domain in the S1 subunit of the SARS-CoV-2 spike protein (anti-S1 IgG antibody). Anti-S1 IgG antibody titers are reported as binding antibody unit per mL (BAU/mL) with a range of 7.1–5680 BAU/mL [6]. Additionally, we examined serum immunoglobulin levels and conducted lymphocyte subset analysis of CD4+ and CD8+ positive T cells, B cells, and NK cells in collected blood samples.

2.4. Endpoints and statistical analysis

The primary endpoint was set as the proportion of subjects acquiring anti-S1 IgG antibodies. According to the manufacturer’s instructions, seropositivity against the SARS-CoV-2 spike protein was defined by an anti-S1 IgG antibody titer of >7.1 BAU/mL [6]. The antibody titer of seronegative patients was set to 0 BAU/mL. Then, we calculated the geometric mean titers (GMT) to analyze the anti-S1 IgG antibodies, with the antibody titers of seronegative patients substituted as 1 BAU/mL, and we used the log-transformed values for the statistical analysis. We compared the GMT of anti-S1 IgG antibody titers in subgroups divided by conditioning regimens, donor type, immunosuppressant intake, and additional agents for GVHD prophylaxis and time elapsed between transplantation and vaccination (<6 months and >6 months). In addition, we compared the GMT of anti-S1 antibodies in subgroups defined by cutoffs of 700, 80, and 40 mg/dL for IgG, IgA, and IgM, respectively, and a total lymphocyte count of 1.0 × 10^9/L, B cell fraction of 3%, and CD4-positive T cell count of 0.4 × 10^9/L [4,7,8].

Adverse events after vaccination and objective deterioration of chronic GVHD were considered as secondary endpoints. Continuous variables were summarized using medians and interquartile range (IQR; quartiles 1–3) or 95% confidence interval (95%CI), whereas categorical variables were summarized as counts and percentages. Seropositivity rates were compared using chi-square test. The GMT of anti-S1 antibody titers between patients and healthy volunteers or among subgroups were compared using the Mann–Whitney U test. Statistical significance was set at P < 0.05. All statistical analyses were performed using R software (version 4.1.2; R Development Core Team).

3. Results

3.1. Patient characteristics

This study included in total 44 allo-HSCT recipients (20 [45%] men, median age 56 [IQR 40–63] years) and 38 healthy controls (9 [24%] men, median age 28 [IQR 25–40] years). All participants did not get infected with COVID-19 before vaccination and were included in final analysis. The characteristics of patients and healthy volunteers are listed in Table 1. Thirty-eight patients (86%) received BNT162b2, whereas six (14%) received mRNA-1273. The median time from the day of transplantation to the first vaccination was 809 days (IQR: 370–1500). The number of patients receiving allo-HSCT within <6 or >6 months was 5 (11%) and 39 (89%), respectively. Of the 44 patients, 16 (36%) were diagnosed with acute myeloid leukemia or myelodysplastic syndromes, 16 (36%) with lymphomas, 8 (18%) with acute lymphoblastic leukemia, and 4 (9%) with other hematological diseases. Moreover, 41 patients (93%) were in complete remission, 1 was not in complete remission, and 2 were on active therapy. Nine patients (20%) have received rituximab; eight for the treatment of B-cell malignancy before allo-HSCT and one for the treatment of post-transplant lymphoproliferative disorders after allo-HSCT. Among them, one patient received rituximab within 12 months before vaccination, and the others received over 12 months before vaccination. Seventeen patients (39%) had one or more chronic GVHD signs or symptoms at inclusion. At vaccination, 20 (45%) patients received one or more immunosuppressive agents.

Immunoassay data revealed that 35 (80%), 36 (82%), and 36 (82%) patients had IgG, IgA, and IgM titers of >700 mg/dL, >80 mg/dL, and
Table 1
Characteristics of patients and healthy volunteers.

| Characteristic                                      | Patients (n = 44) | Healthy volunteers (n = 38) |
|-----------------------------------------------------|------------------|----------------------------|
| Age, median (IQR), years                           | 56 (40, 63)      | 28 (25, 40)                |
| Sex, n (%)                                          |                  |                            |
| Male                                                | 20 (45%)         | 9 (24%)                    |
| Female                                              | 24 (55%)         | 29 (76%)                   |
| Vaccine, n (%)                                      |                  |                            |
| BNT162b2                                            | 38 (86%)         | 38 (100%)                  |
| mRNA1273                                            | 6 (14%)          | 0 (0%)                     |
| IgG, median (IQR), mg/dL                            | 1016             | 1158                       |
| >700 mg/dL, n (%)                                   | 35 (80%)         | 38 (100%)                  |
| ≤700 mg/dL, n (%)                                   | 9 (20%)          | 0 (0%)                     |
| IgA, median (IQR), mg/dL                            | 133 (103-214)    | 180 (150-250)              |
| >80 mg/dL, n (%)                                    | 36 (82%)         | 38 (100%)                  |
| ≤80 mg/dL, n (%)                                    | 8 (18%)          | 0 (0%)                     |
| IgM, median (IQR), mg/dL                            | 70 (48-110)      | 108 (73-141)               |
| >40 mg/dL, n (%)                                    | 36 (82%)         | 37 (97%)                   |
| ≤40 mg/dL, n (%)                                    | 8 (18%)          | 1 (2.6%)                   |
| WBC, median (IQR) × 10³/μL                          | 5.75             | 6.156                      |
| Lymphocytes, median (IQR) × 10⁸/μL                  | 1.748            | 1.393                      |
| >1.0 × 10⁸/μL, n (%)                                | 39 (89%)         | 34 (89%)                   |
| ≤1.0 × 10⁸/μL, n (%)                                | 5 (11%)          | 4 (11%)                    |
| B cells, median (IQR)/μL                            | 334 (203-566)    | 151 (113-212)              |
| B cell fraction in total lymphocytes, median (IQR) | 21% (13%-27%)    | 11% (9%-15%)               |
| ≤3%, n (%)                                          | 5 (11%)          | 0 (0%)                     |
| ≤3%, n (%)                                          | 39 (89%)         | 38 (100%)                  |
| T cells, median (IQR)/μL                            | 1047             | 956 (785–1239)             |
| CD4+ T cells, median (IQR)/μL                       | 452 (244-672)    | 519 (451-692)              |
| >0.4 × 10⁹/μL, n (%)                                | 26 (59%)         | 33 (87%)                   |
| ≤0.4 × 10⁹/μL, n (%)                                | 18 (41%)         | 5 (13%)                    |
| NK cells, median (IQR)/μL                           | 244 (123-437)    | 207 (168-313)              |
| Diseases, n (%)                                     |                  |                            |
| AML/MDS                                             | 16 (36%)         |                            |
| Lymphomas                                           | 16 (36%)         |                            |
| ALL                                                 | 8 (18%)          |                            |
| Others                                              | 4 (9%)           |                            |
| Disease status a, n (%)                             |                  | N/A                        |
| Complete remission                                  | 41 (93%)         |                            |
| Not in complete remission                           | 1 (2.3%)         |                            |
| On active therapy                                   | 2 (4.5%)         |                            |
| Chronic GVHD, n (%)                                 |                  | N/A                        |
| Yes                                                 | 17 (39%)         |                            |
| No                                                  | 27 (61%)         |                            |
| Conditioning regimen, n (%)                         |                  | N/A                        |
| Myeloablative Conditioning                          | 21 (48%)         |                            |
| Reduced Intensity Conditioning                      | 23 (52%)         |                            |
| Donor, n (%)                                        |                  | N/A                        |
| Matched Related, PB                                 | 11 (25%)         |                            |
| Mismatched Related, PB                              | 1 (2%)           |                            |
| Matched Unrelated, PB or BM                         | 3 (7%)           |                            |
| Mismatched Unrelated, PB or BM                       | 5 (11%)          |                            |
| Haploidentical, PB                                  | 18 (41%)         |                            |
| Umbilical Cord Blood                                | 8 (18%)          |                            |
| GVHD prophylaxis regimen, n (%)                     |                  | N/A                        |
| Tacrolimus-based                                    | 43 (98%)         |                            |
| Cyclosporin-based                                   | 1 (2%)           |                            |
| Additional agents for GVHD prophylaxis, n (%)       |                  | N/A                        |
| Post-transplant cyclophosphamide                    | 15 (34%)         |                            |
| Anti-thymocyte globulin                             | 5 (11%)          |                            |
| Immunosuppressive agent intake at vaccination, n (%)| 20 (45%)         | N/A                        |
| Prednisolone alone                                  | 9 (20%)          |                            |
| Calcineurin inhibitor alone                         | 6 (14%)          |                            |
| Calcineurin inhibitor plus prednisoloned            | 5 (11%)          |                            |
| Prednisolone intake at vaccination, n (%)           | 14 (32%)         | N/A                        |
| >0.3 mg/kg/day, n (%)                               | 2 (4.5%)         |                            |
| ≤0.3 mg/kg/day, n (%)                               | 12 (27.3%)       |                            |

The previous administration of anti-CD20 monoclonal antibodies, n (%) a
Within 12 months before vaccination | 1 (2%) |
Over 12 months before vaccination | 8 (18%) |

Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; BM, bone marrow; GVHD, graft versus host disease; IQR, interquartile range; MDS, myelodysplastic syndromes; N/A, not applicable; PB, peripheral blood; WBC, white blood cells.

- One patient who has received second allogeneic hematopoietic stem cell transplantation for ALL was included.
- Two patients had aplastic anemia, one had chronic myeloid leukemia, and one had multiple myeloma.
- A patient not in complete remission; an AML patient at relapse awaiting the salvage chemotherapy. Patients on active therapy; a CLL patients on ibrutinib for relapse and an AML patient on salvage chemotherapy.
- One patient had received mycophenolate mofetil in addition to calcineurin inhibitor and prednisolone.
- Eight patients received rituximab for the treatment of B-cell malignancies, and one received for post-transplant lymphoproliferative disorders.
- Two patients had diffuse large B-cell lymphoma, not otherwise specified and two had multiple myeloma.

- >40 mg/dL, respectively, and 39 (89%) patients had a total lymphocyte count of >1.0 × 10⁸/μL, 39 (39%) had B cell fraction of >3%, and 26 (59%) had a CD4-positive T cell count of >0.4 × 10⁶/μL.

3.2. Serological response

Antibody response against the vaccine was evident in 40 (91%) patients and in all 38 healthy controls. The GMT of anti-S1 titers in patients and healthy controls were 277 (95%CI: 120–643) BAU/mL and 532 (95%CI: 400–708) BAU/mL (P = 0.603), respectively (Fig. 1). Details of four seronegative allo-HSCT recipients were as follows: a chronic lymphocytic leukemia patient on ibrutinib for relapse after allo-HSCT, a T-cell prolymphocytic leukemia patient who had received alemtuzumab before allo-HSCT, an angioimmunoblastic T-cell lymphoma patient who also had B-cell lymphoproliferative disease and received rituximab before allo-HSCT within 12 months before vaccination, and an acute myeloid leukemia patient on tacrolimus and prednisolone (35 mg/day) for active chronic GVHD.

In subgroup analysis, a short time interval between transplantation and vaccination (≤6 months) was associated with low anti-S1 IgG antibody titers (Fig. 1, Table 2). Of note, however, four out of five patients revealed detectable anti-S1 IgG titers, with median titers of 21.2 (95% CI: 1.27–357) in GMT. Even among allo-HSCT recipients, those with longer time intervals between transplantation and vaccination (n = 39, >6 months, median 975 [IQR: 631–1638] days) exhibited median anti-S1 IgG titers of 386 (95%CI: 164–905) BAU/mL in GMT, which is compatible with those of healthy controls (Fig. 1).
We also conducted an exploratory subgroup analysis and found that lymphocytopenia \( \leq 1.0 \times 10^3/\mu L \), peripheral B cell fraction \( \leq 3\% \), hypogammaglobulinemia, immunosuppressant intake at vaccination were associated with impaired humoral response (Table 2).

### 3.3. Adverse events and the break-through SARS-CoV-2 infection

All patients and healthy volunteers reported adverse events after the first and second vaccinations. Local pain at the injection site, fatigue, and fever were common in both groups and were reported in 92%, 50%, and 37% of healthy volunteers, respectively, and 77%, 34%, and 14% of patients, respectively, after the second dose (Fig. 2). All adverse events were mild and resolved spontaneously. Two seropositive patients got infected with SARS-CoV-2129 and 160 days after their second vaccination. The two had mild diseases and were managed with sotrovimab and remdesivir.

### 3.4. Deterioration of chronic GVHD

NIH score was recorded by attending physicians on the days of inclusion and blood sampling. Among 17 patients (38.6%) with one or more chronic GVHD signs and NIH score of more than one point at inclusion, only 1 patient had worsened NIH score (5–7), 7 had improved NIH score, and 9 had the same NIH score on the day of blood sampling. The patient whose NIH score worsened revealed deteriorated performance status due to lung abscess caused by bacterial infection. Among nine patients whose NIH scores remained stable, one reported subjective worsening of dry eye and limited range of motion, which resolved spontaneously. Among 27 patients (61.3%) whose NIH score at inclusion was zero, only one patient revealed a worsened NIH score (0–1) at the time of blood sampling due to a newly developed skin rash that required topical steroid ointment application. Furthermore, another patient reported the occurrence of dry eye within 1 week from vaccination, which resolved spontaneously (Fig. 2).

### 4. Discussion

This study prospectively evaluated the humoral response of allo-HSCT recipients to COVID-19 mRNA vaccines BNT162b2 (BioNTech Pfizer) and mRNA-1273 (Moderna). We observed that allo-HSCT recipients respond well to mRNA COVID-19 vaccines. However, vaccination within 6 months from allo-HSCT was associated with low anti-S1 IgG titers. In terms of safety, no additional adverse events were observed in the allo-HSCT group compared to control group. In addition, no severe development or deterioration of chronic GVHD was reported.

Our study showed a high seropositivity rate in allo-HSCT recipients, compatible with healthy controls. Some previous studies that investigated the effectiveness of mRNA COVID-19 vaccines in allo-HSCT recipients reported a higher seropositivity rate (50%–80%) in these patients compared with solid organ transplant recipients (40%–60%) and anti-CD20 antibody recipients (<20% if anti-CD20 antibodies were administered within 6–12 months) [9–14]. However, these studies also indicated that humoral responses of allo-HSCT recipients to mRNA COVID-19 vaccines were weaker than those of healthy individuals [10–14]. Our study revealed a higher seropositivity to mRNA COVID-19 vaccines among allo-HSCT patients than previous reports. This is probably because our study included many patients with a longer time interval between transplantation and vaccination (median duration of 809 [IQR: 370–1500] days) compared to previous studies. This seems advantageous to expect reconstruction of adaptive immunity to gain seroconversion after vaccination [3]. In addition, the timing of serological assessment after the second dose of allo-HSCT recipients was earlier than that of volunteers (the median 37 versus 79 days, respectively). Therefore, it can result in the lower anti-S1 IgG titers of volunteers due to a decline over time. Our study also revealed that a short time interval between transplantation and vaccination (≤6 months) was
associated with low anti-S1 IgG antibody titers. Nevertheless, our results are encouraging and support the recommendation of the American Society of Hematology and American Society of Transplantation and Cellular Therapy.

Anti-S1 IgG titers have been reported to be associated with neutralization activity against SARS-CoV-2; however, an observational study has indicated that neutralization activity is absent if anti-S1 antibody levels are low [15]. Among allo-HSCT recipients with a detectable but weak humoral response after the administration of two doses of an mRNA COVID-19 vaccine, an increase in antibody levels after the administration of a third dose has been observed [11]. Therefore, allo-HSCT recipients who received mRNA COVID-19 vaccines early after transplantation would benefit from an additional dose of mRNA COVID-19 vaccines. Keeping up-to-date on vaccination, allo-HSCT recipients should continue strict protective measures, such as wearing masks and social distancing.

In addition to a short time interval between allo-HSCT and vaccination [11,16,17], various factors, such as conditioning regimen (e.g., reduced intensity conditioning) [16], donor type (e.g., haploidentical donors) [10,16,17], immunosuppressant intake [11,12,17–19], GVHD presence [16], hypogammaglobulinemia [15,19], and lymphocytopenia [10,11,15,17,19,20] have been proposed as the potential predictors of impaired humoral response. Our study indicates that immunosuppressive agent use, hypogammaglobulinemia, lymphocytopenia, and low B-cell fraction (<3%) is associated with impaired humoral response, which is in line with some previous reports. Haploidentical peripheral blood was the leading donor type of the patient cohort in our study, which was relatively unique to our study. However, we did not observe significant difference of anti-S1 IgG titers between haploidentical peripheral blood and other donor types. Systematic review and meta-analysis uniting the existing reports would be necessary to establish the predictor of impaired responses.

No serious adverse events were observed in both patients and healthy volunteers in our study. Since mRNA vaccines have a high immunogenicity, there is concern regarding activation of inflammatory pathways, which might lead to immune-related adverse events, including the deterioration of chronic GVHD [12,21,22]. Regarding this concern, previous studies have reported that <10% of allo-HSCT recipients experienced deterioration or new development of chronic GVHD, most of which were easy to control. In our study, only one case of mild deterioration of existing chronic GVHD and one case of newly developed skin rash that required topical steroid ointment application. Among other 42 patients, NIH scores of the remaining 42 patients were either stable (gray lines) or improved (blue lines).

![Fig. 2. (a and b) Adverse events reported after the first and second dose of mRNA vaccines. The percentage of responders among (a) allo-HSCT recipients and (b) healthy volunteers declaring one or more adverse events. (c) Change in NIH chronic GVHD scores at inclusion (before vaccination) and blood sampling after two doses of vaccines. Among 44 patients, only 2 patients exhibited deteriorated NIH score (red lines). One case exhibited worsened performance status (NIH score five to seven) due to lung abscess caused by bacterial infection and was not relevant to the exacerbation of chronic GVHD. The other (NIH score zero to one) was a case of newly developed skin rash that required topical steroid ointment application. Among other 42 patients, NIH scores of the remaining 42 patients were either stable (gray lines) or improved (blue lines).](image-url)
this study had a heterogeneous background. The sample size was too small to establish a predictor of the impaired humoral response. Second, the cohort of healthy individuals for the comparison is not comparable with patients on the two parameters: the age and timing of antibody assessment. Humoral response to mRNA-based COVID-19 vaccines substantially decreases over time after it reaches the peak at two weeks after the completion of two doses of vaccination [24]. In our study, the timing of serological assessment of healthy controls was 42 days later than that of allo-HSCT recipients. Therefore, it should be noted that if serological assessment was conducted at the same time, healthy volunteers may yield the higher anti-S1 IgG titers, which can result in the statistical difference between patients and volunteers. Third, we excluded participants with reported COVID-19. Negative results in an analysis and manuscript writing, editing, and review. H.M., S.N., T.N., M.N. wrote the manuscript and Y.S. supervised the statistical data. N.O., D.N., K.K., H.I., R.Y., Y.N., N.H., S.Y., N.Y., A.M., and T.I. collected data and provided patient information. Y.S. and T.I. coordinated the project and edited the manuscript. C.M. provided comments on statistical analysis. A.D. provided comments on epidemiology and infection control. All authors have read and approved the final manuscript.

Data availability statement

The datasets generated and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Clinical trial registration

This study was registered with the University Hospital Medical Information Network (UMIN) in Japan (UMIN000046044).

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Patient consent statement

Informed consent was obtained from all participants.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgments

The authors would like to thank the nurses at the Hematology Department and laboratory staff at the Clinical Laboratory Department and LSI Medience Laboratory of Kobe City Medical Center General Hospital.

References

[1] Sharma A, Bharti NS, St Martin A, Abid MB, Bloomquist J, Chemaly RF, et al. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study (published correction appears in Lancet Haematol). Lancet Haematol 2021;8:e185–93. https://doi.org/10.1016/S2352-3026(20)30429-4. 2021 Jun;8(6):e993.
[2] The American society of transplantation and cellular therapy and the American society of Hematology. ASH-ASTCT COVID-19 vaccination for HCT and CAR T cell recipients: frequently asked questions. https://www.hematology.org/covid-19/a-sh-astct-covid-19-vaccination-for-hct-and-car-t-cell-recipients. [Accessed 20 March 2022].
[3] Cordonnier C, Einardottir S, Cesario S, Di Blasi R, Mikulska M, Rieger C, et al. Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECLI). 7. Lancet Infect Dis 2019; 19:e200-12. https://doi.org/10.1016/S1473-3099(18)30660-5.
[4] Nishikubo M, Shimomura Y, Maruoka H, Nau S, Nishikoba T, Sakizono K, et al. Humoral response and safety of the BNT162b2 and mRNA-1273 COVID-19 vaccines in patients with haematological diseases treated with anti-CD20 antibodies: an observational study. Br J Haematol 2022;197:709–13. https://doi.org/10.1111/bjh.18151.
[5] Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transplant 2015;21:389–401. https://doi.org/10.1016/j.bbmt.2014.12.001, e1.
[6] Abbott Laboratories. Diagnostics division. SARS-CoV-2 igG – instructions for use. Archive. https://www.fda.gov/media/137383/download. [Accessed 10 October 2022].
[7] Perry C, Luttkau E, Balsan R, Shefer G, Morales MM, Aharon A, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma. Blood Adv 2021;5:3053-61. https://doi.org/10.1182/bloodadvances.2021005094.
[8] Benjamini O, Rokach L, Ichaki G, Braester A, Shvidel L, Goldschmidt N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Haematologica 2022;107:625–34. https://doi.org/10.3324/haematol.2021.279196.
[9] Herishanu Y, Avivi I, Aharon A, Shefer G, Levi S, Bronstein Y, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood 2021;137:e365-73. https://doi.org/10.1182/blood.2021011568.
[10] Piñana JL, López-Corral I, Martino R, Montoro J, Varquez I, Pérez A, et al. SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group. Am J Hematol 2022;97:30-42. https://doi.org/10.1002/ajh.26385.
[11] Maillard A, Redjoul R, Klemenc M, Labussière Wallot H, Le Bourgeois A, D’Avend R, et al. Antibody response after 2 and 3 doses of SARS-CoV-2 mRNA vaccine in autologous hematopoietic cell transplant recipients. Blood 2022;139: 134-7. https://doi.org/10.1182/blood.2021014232.
[12] Bergman P, Blennow O, Hanstén L, Mielke S, Nowak P, Chen P, et al. Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial. EBioMedicine 2021;74:103705.
[13] Redjoul R, Le Bouter A, Beckerich F, Fourati S, Maury S. Antibody response after second BNT162b2 dose in autologous HSCT recipients. Lancet 2021;398:298-9. https://doi.org/10.1016/S0140-6736(21)01107-1.
[14] Maneikis K, Šablaukas K, Ringlevičius U, Vaitkevienė V, Cekušiukienė R, Kryžiaukaitė I, et al. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study. Lancet Haematol 2021;8:e583-92. https://doi.org/10.1016/S2352-3026(21)00169-1.
[15] Tamari R, Politikos I, Knorr DA, Vardhmana SA, Young JC, Marcello LT, et al. Predictors of humoral response to SARS-CoV-2 vaccination after hematopoietic cell
transplantation and CAR T-cell therapy. Blood Cancer Discov 2021;2:577–85. https://doi.org/10.1158/2643-3230.BCD-21-0142.

[16] Shem-Tov N, Yorushalmi R, Danylesko I, Litachevsky V, Levy I, Olmer L, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in haematopoietic stem cell transplantation recipients. Br J Haematol 2022;196:884–91. https://doi.org/10.1111/bjh.17918.

[17] Le Bourgeois A, Coste-Burel M, Guillaume T, Peterlin P, Garnier A, Béné MC, et al. Safety and antibody response after 1 and 2 doses of BNT162b2 mRNA vaccine in recipients of allogeneic haematopoietic stem cell transplant. JAMA Netw Open 2021;4:e2126344. https://doi.org/10.1001/jamanetworkopen.2021.28844.

[18] Ge C, Du K, Luo M, Shen K, Zhou Y, Guo K, et al. Serologic response and safety of COVID-19 vaccination in HSCT or CAR T-cell recipients: a systematic review and meta-analysis. Exp Hematol Oncol 2022;11:46. https://doi.org/10.1186/s40164-022-00299-6.

[19] Tsushima T, Terao T, Narita K, Fukumoto A, Ikeda D, Kamura Y, et al. Antibody response to COVID-19 vaccine in 130 recipients of hematopoietic stem cell transplantation. Int J Hematol 2022;115(5):611–5. https://doi.org/10.1007/s12185-022-03225-9.

[20] Majcherek M, Matkowska-Kocjan A, Szymczak D, Karasek M, Szeremet A, Kiraga A, et al. Two doses of BNT162b2 mRNA vaccine in patients after hematopoietic stem cell transplantation: humoral response and serological conversion predictors. Cancers 2022;14:325. https://doi.org/10.3390/cancers14020325.

[21] Ali H, Ngo D, Aribi A, Arslan S, Dadwal S, Marcucci G, et al. Safety and tolerability of SARS-CoV2 emergency-use authorized vaccines for allogeneic hematopoietic stem cell transplant recipients. Transplant Cell Ther 2021;27. https://doi.org/10.1016/j.jtct.2021.07.008, 938.e1-938938.e6.

[22] Ram R, Hagan D, Kikozashvilli N, Fresund T, Amit O, Bar-On Y, et al. Safety and immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in patients after allogeneic HCT or CD19-based CART therapy-A single-center prospective cohort study. Transplant Cell Ther 2021;27:788–94. https://doi.org/10.1016/j.jtct.2021.06.024.

[23] Watanabe M, Yakuhiijin K, Furukoshi Y, Ohji G, Hojo W, Sakai H, et al. The safety and immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in Japanese patients after allogeneic stem cell transplantation. Vaccines (Basel) 2022;10:158. https://doi.org/10.3390/vaccines10020158.

[24] Levin BG, Lustig Y, Cohen C, Fluss R, Indenbourm V, Amit S, et al. Waning immune humoral response to BNT162b2 covid-19 vaccine over 6 months. N Engl J Med 2021;385(24):e84. https://doi.org/10.1056/NEJMoa2114583.

[25] Grinshpun A, Rottenberg Y, Ben-Dov IZ, Dijan E, Wolf DG, Kadouri L. Serologic response to COVID-19 infection and/or vaccine in cancer patients on active treatment. ESMO Open 2021;6:100283. https://doi.org/10.1016/j.esmoop.2021.100283.

[26] Schwarzkopf S, Krawczyk A, Knop D, Klump H, Heinold A, Heinemann FM, et al. Cellular immunity in COVID-19 convalescents with PCR-confirmed infection but with undetectable SARS-CoV-2-specific IgG. Emerg Infect Dis 2021;27. https://doi.org/10.3201/2701.203772, 10.3201/2701.203772.

[27] Marasco V, Carniti C, Guidetti A, Farina L, Magni M, Miceli R, et al. T-cell immune response after mRNA SARS-CoV-2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies. Br J Haematol 2022;196:548–58. https://doi.org/10.1111/bjh.17877.